BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Income Statement
NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 503.49M | 450.71M | 331.41M | 270.80M | 157.20M | |||
| Cost Of Goods | 15.66M | 12.48M | 4.66M | 6.60M | 7.30M | |||
| Gross Profit | 487.82M | 438.23M | 326.75M | 264.20M | 149.90M | |||
| Operating Expenses | 454.65M | 440.77M | 428.91M | 412.70M | 327.60M | |||
| Research and Development | 165.41M | 174.64M | 215.02M | 253.30M | 208.80M | |||
| Selling, General, and Administrative Expenses | 289.24M | 266.13M | 213.89M | 159.40M | 118.80M | |||
| Operating Income | 33.17M | -2.54M | -102.16M | -148.40M | -177.70M | |||
| Interest Income/Expense | -84.35M | -84.41M | -93.50M | -95.90M | -59.90M | |||
| Non Recurring Items | N/A | 0.00 | -30.57M | 0.00 | 55.80M | |||
| Income Before Taxes | -51.18M | -86.95M | -226.23M | -244.40M | -181.80M | |||
| Income Tax | 2.29M | 1.93M | 310.00K | 2.70M | 2.30M | |||
| Net Income | -53.47M | -88.88M | -226.54M | -247.10M | -184.10M | |||
| EBITDA | 34.44M | -1.30M | -100.51M | -146.96M | -176.92M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.26 | -0.43 | -1.18 | -1.33 | -1.03 | |||
| Non GAAP EPS | -0.26 | -0.43 | -0.99 | -1.33 | -1.03 | |||
| Statistics | ||||||||
| Gross Profit Margin | 96.89% | 97.23% | 98.59% | 97.56% | 95.36% | |||
| Profit Margin | -10.62% | -19.72% | -68.36% | -91.25% | -117.11% | |||
| Operating Profit Margin | 6.59% | -0.56% | -30.83% | -54.80% | -113.04% | |||
All data in USD